KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Chemed (CHE) EBITDA (2016 - 2025)

Chemed (CHE) has 17 years of EBITDA data on record, last reported at -$149.1 million in Q4 2025.

  • For Q4 2025, EBITDA rose 4.08% year-over-year to -$149.1 million; the TTM value through Dec 2025 reached $129.3 million, down 5.47%, while the annual FY2025 figure was $129.3 million, 5.47% down from the prior year.
  • EBITDA reached -$149.1 million in Q4 2025 per CHE's latest filing, down from $88.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $124.4 million in Q4 2023 and bottomed at -$180.8 million in Q4 2022.
  • Average EBITDA over 5 years is $58.4 million, with a median of $92.6 million recorded in 2021.
  • Peak YoY movement for EBITDA: soared 172.55% in 2021, then plummeted 264.6% in 2022.
  • A 5-year view of EBITDA shows it stood at $109.9 million in 2021, then tumbled by 264.6% to -$180.8 million in 2022, then skyrocketed by 168.8% to $124.4 million in 2023, then plummeted by 224.95% to -$155.5 million in 2024, then rose by 4.08% to -$149.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$149.1 million in Q4 2025, $88.4 million in Q3 2025, and $81.8 million in Q2 2025.